Alliance Global lowered the firm’s price target on Acurx (ACXP) to $10 from $20 and keeps a Buy rating on the shares following the Q4 report. The firm pushed back its expected FDA approval of ibezapolstat for C. difficile infection to 2031 from 2028, but says the new open label Phase 2 “will afford the opportunity for additional data quicker and cheaper.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Acurx reports Q4 EPS (73c) vs. ($3.29) last year
- Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate
- ACXP Earnings this Week: How Will it Perform?
- Acurx Advances Ibezapolstat Program for Recurrent C. difficile
- Acurx announces new ibezapolstat clinical trial program